GlassScriptPhysician profile
Waseem Mir
NPI 1376714469
$24,435.40
in general payments reported to CMS, 2019-2025
42 companies · $4,405 in 2025
The $4,405 reported for 2025 was more than what 97% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,796 · 2020: $2,829 · 2021: $2,843 · 2022: $3,504 · 2023: $4,229 · 2024: $3,829 · 2025: $4,405.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $54.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,408.66 |
| Education | $54.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,967.83 | 2019-2025 | |
| Amgen INC. | $3,242.96 | 2019-2025 | Tavneos, Krystexxa, Evenity |
| Janssen Biotech, INC. | $2,167.51 | 2019-2025 | Tremfya |
| Ucb, INC. | $1,874.70 | 2019-2025 | Cimzia, Bimzelx |
| Pfizer INC. | $1,656.03 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,380.43 | 2019-2025 | Benlysta |
| Novartis Pharmaceuticals Corporation | $1,182.72 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $1,177.72 | 2020-2025 | Acthar |
| Astrazeneca Pharmaceuticals LP | $1,006.74 | 2021-2025 | Saphnelo, Evusheld |
| Lilly USA, LLC | $838.36 | 2019-2025 | Taltz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $802.11 | 2019-2025 | Cyltezo, Ofev, Spevigo |
| Genentech USA, INC. | $716.83 | 2019-2025 | Actemra |
| Radius Health, INC. | $637.17 | 2019-2025 | Tymlos |
| Merz North America, INC. | $625.00 | 2022-2023 | Xeomin |
| E.R. Squibb & Sons, L.L.C. | $574.86 | 2019-2025 | Orencia |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $296.53 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $281.90 | 2019-2020 | |
| Bioventus LLC | $247.34 | 2019-2024 | Gelsyn-3, Supartz Fx Sodium Hyaluronate |
| Janssen Pharmaceuticals, INC | $194.52 | 2025 | Tremfya |
| Depuy Synthes Sales INC. | $174.62 | 2019-2025 | Orthovisc, Monovisc |
| Alexion Pharmaceuticals, INC. | $171.94 | 2021-2025 | Strensiq |
| Horizon Therapeutics Plc | $158.38 | 2019-2023 | Krystexxa |
| Genzyme Corporation | $147.79 | 2021-2025 | |
| Ani Pharmaceuticals, INC. | $108.58 | 2024 | Purified Cortrophin Gel |
| Fresenius Kabi USA, LLC | $84.92 | 2023 | Idacio |
| Aurinia Pharma U.S., INC. | $82.77 | 2021-2025 | Lupkynis |
| Ultragenyx Pharmaceutical INC. | $82.22 | 2021-2023 | Crysvita |
| Sandoz INC. | $70.70 | 2023-2025 | Hyrimoz |
| Scilex Pharmaceuticals INC. | $65.66 | 2024-2025 | |
| Allergan, INC. | $59.79 | 2021-2022 | |
| Medexus Pharma, INC. | $56.25 | 2019-2020 | |
| Celgene Corporation | $53.14 | 2019 | |
| Ferring Pharmaceuticals INC. | $34.72 | 2021 | |
| Octapharma USA, INC. | $31.16 | 2025 | Octagam Immune Globulin (Human) |
| Sobi, INC | $30.22 | 2025 | |
| Zimmer Biomet Holdings, INC. | $24.44 | 2024 | Visco-3 Sodium Hyaluronate |
| Alvogen INC | $23.99 | 2025 | Teriparatide |
| Gilead Sciences, INC. | $23.98 | 2020 | |
| Invivyd INC | $21.14 | 2025 | Pemgarda |
| Oxford Immunotec USA INC | $20.21 | 2022 | |
| Shorla Oncology INC. | $19.28 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $18.24 | 2025 | Opsynvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Waseem Mir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.